Navigation Links
Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
Date:7/22/2014

BURLINGTON, Mass., July 22, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing and/or gastrointestinal events while on the therapy. However, few Tecfidera-treated patients are currently experiencing these side effects, signifying either their transient nature or the effective medical management of such events. In the end, fewer than 15 percent of surveyed neurologists felt that Tecfidera-related side effects were an obstacle to their prescribing of the product.

Other key findings from the ChartTrends: Multiple Sclerosis 2014 (US) report:

  • Anti-JC virus antibody testing: The majority of patients tested for anti-JC virus antibodies were treatment naive or were on a DMT other than Biogen Idec's Tysabri at the time of testing, supporting neurologists' reporting that the main driver of assay testing is related to patients' potential candidacy for Tysabri. However, patients (regardless of serostatus) were more likely to stay on their original DMT than switch to another DMT for up to two years after testing.
  • Market potential of emerging therapies: When neurologists hypothetically chose one of the emerging products profiled to switch the audit patient to, Biogen Idec's Plegridy—the product likely to reach the market first—was most frequently selected. Over half of surveyed neurologists believe that Plegridy is most likely to replace the interferon-beta-1a therapy Biogen Idec's Avonex, however patient-level data suggest that the impact of Plegridy is more likely to be spread across the platform injectable DMTs.

Comments from Decision Resources Group Analyst Emma McFadden, Ph.D.:

  • "Although it is still uncertain when, or even if, generic versions of Teva's Copaxone 20 mg will be approved by the FDA, neurologists indicated that they plan to switch approximately one-fifth of audit patients to generic glatiramer acetate once available. While it is not surprising that Copaxone 20 mg appears to be most at risk for generic switching, it is interesting to note that Tecfidera- and Tysabri-treated patients appear to be least likely to be switched, alluding to neurologists' perception that these products have characteristics that justify the additional cost or reimbursement effort."
  • "Analysis of candidates for the emerging monoclonal antibodies Genzyme/Sanofi's Lemtrada and Genentech/Roche's ocrelizumab suggests that these DMTs would likely be prescribed to patients with more severe/aggressive MS and potentially compete with Tysabri, the DMT typically initiated when efficacy reasons are the main drivers of brand choice. Given Tysabri's general position in the MS treatment algorithm as a third-line or later option, these emerging agents will be reserved primarily for patients who have failed earlier lines of therapy."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
2. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
3. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
4. Sinovac Reports Unaudited First Quarter 2012 Financial Results
5. SCOLR Pharma Announces Unaudited Net Sales of Nutritional Products
6. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
7. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2012 Results
8. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
9. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
10. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
11. Groupe Athena Inc., (OTC: GATA) Reports Audited Financials, Announces Record Revenue & Profits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 ... , and OptiMed Specialty Pharmacy of Kalamazoo, ... offer a strategic hub service that expedites and streamlines ... personal spirometer, Spiro PD 2.0, and wellness management services.  ... is a medical device used to measure lung function ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of ... Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, ... In honor of Morris F. Collen, a pioneer in the field of medical informatics, ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
Breaking Medicine News(10 mins):